Making capecitabine targeted therapy for breast cancer: Which is the role of thymidine phosphorylase?

Clinical Breast Cancer

Volumn 13, Issue 3, 2013, Pages 167-172

  Bonotto, Marta ^a   Bozza, Claudia ^a   Di Loreto, Carla ^a,b   Osa, Etin Osa O ^c   Poletto, Elena ^a   Puglisi, Fabio ^a,b  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Capecitabine; Immunohistochemistry; Predictive factor; Prognostic marker; Thymidine phosphorylase

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; FLUOROPYRIMIDINE; FLUOROURACIL; KI 67 ANTIGEN; MESSENGER RNA; PLACEBO; TAXANE DERIVATIVE; THYMIDINE PHOSPHORYLASE;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CELL STRESS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; HUMAN; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PREDICTOR VARIABLE; PREOPERATIVE TREATMENT; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84876707206     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2012.10.002     Document Type: Review

References (46)

1. P.A. Greenberg, G.N. Hortobagyi, T.L. Smith Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer J Clin Oncol 14 1996 2197 2205
2. S. Dawood, K. Broglio, A.M. Gonzalez-Angulo Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer J Clin Oncol 26 2008 4891 4898
3. S.K. Chia, C.H. Speers, Y. D'yachkova The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer Cancer 110 2007 973 979
4. B.E. Kiely, Y.Y. Soon, M.H. Tattersall How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials J Clin Oncol 29 2011 456 463
5. D. Mauri, N.P. Polyzos, G. Salanti Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer J Natl Cancer Inst 100 2008 1780 1791
6. C. Andreetta, A.M. Minisini, M. Miscoria First-line chemotherapy with or without biologic agents for metastatic breast cancer Crit Rev Oncol/Hematol 76 2010 99 111
7. Xeloda: (capecitabine) tablets [prescribing information] http://www.rocheusa.com/products/xeloda/pi.pdf Accessed: March 23, 2006
8. G. Aprile, M. Mazzer, S. Moroso Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer Anticancer Drugs 20 2009 217 229
9. M. Miwa, M. Ura, M. Nishida Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1998 1274 1281
10. M. Toi, M. Atiqur Rahman, H. Bando Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment Lancet Oncol 6 2005 158 166
11. J. Schüller, J. Cassidy, E. Dumont Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients Cancer Chemother Pharmacol 45 2000 291 297
12. R. Ikeda, T. Furukawa, R. Mitsuo Thymidine phosphorylase inhibits apoptosis induced by cisplatin Biochem Biophys Res Commun 301 2003 358 363
13. S.J. Lee, Y.L. Choi, Y.H. Park Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer Cancer Chemother Pharmacol 68 2011 743 751
14. Q. Yang, M. Barbareschi, I. Mori Prognostic value of thymidine phosphorylase expression in breast carcinoma Int J Cancer 97 2002 512 517
15. R.C. Bast, G.N. Hortobagyi Individualized care for patients with cancer - a work in progress N Engl J Med 351 2004 2865 2867
16. R. Simon Development and validation of biomarker classifiers for treatment selection J Stat Plan Inference 138 2008 308 320
17. D.J. Sargent, B.A. Conley, C. Allegra Clinical trial designs for predictive marker validation in cancer treatment trials J Clin Oncol 23 2005 2020 2027
18. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) C. Davies, J. Godwin et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 2011 771 784
19. R.L. Jones, J. Salter, R. A'Hern Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer Breast Cancer Res Treat 119 2010 315 323
20. A. Di Leo, C. Desmedt, J.M. Bartlett HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data Lancet Oncol 12 2011 1134 1142
21. A. Shery, M. Dowsett Developments in Ki-67 and other biomarkers for treatment decision making in breast cancer Ann Oncol 23 2012 219 227
22. E. De Azambuja, F. Cardoso, G. De Castro Jr. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving; 12.155 patients Br J Cancer 96 2007 1504 1513
23. C.M. Walko, C. Lindley Capecitabine: a review Clin Ther 27 2005 23 44
24. M. Friedkin, D. Roberts The enzymatic synthesis of nucleosides I. Thymidine phosphorylase in mammalian tissue J Biol Chem 207 1954 245 256
25. D.R. Budman, N.J. Meropol, B. Reigner Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine J Clin Oncol 16 1998 1795 1802
26. H. Eda, K. Fujimoto, S. Watanabe Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine Cancer Chemother Pharmacol 32 1993 333 338
27. H. Goto, K. Kohno, S. Sone Interferon gamma-dependent induction of thymidine phosphorylase/platelet-derived endothelial growth factor through gamma-activated sequence-like element in human macrophages Cancer Res 61 2001 469 473
28. M. Fukushima, H. Okabe, T. Takechi Induction of thymidine phosphorylase by interferon and taxanes occurs only in human cancer cells with low thymidine phosphorylase activity Cancer Lett 187 2002 103 110
29. L. Griffiths, G.U. Dachs, R. Bicknell The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo Cancer Res 57 1997 570 572
30. M. Kitazono, Y. Takebayashi, K. Ishitsuka Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase Biochem Biophys Res Commun 253 1998 797 803
31. S. Mori, S. Takao, R. Ikeda Thymidine phosphorylase suppresses Fas-induced apoptotic signal transduction independent of its enzymatic activity Biochem Biophys Res Commun 295 2002 300 305
32. A. Jones, C. Fujiyama, K. Turner Role of thymidine phosphorylase in an in vitro model of human bladder cancer invasion J Urol 167 2002 1482 1486
33. M. Relf, S. LeJeune, P.A. Scott Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis Cancer Res 57 1997 963 969
34. M. Matsumura, Y. Chiba, C. Lu Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression correlated with tumor angiogenesis and macrophage infiltration in colorectal cancer Cancer Lett 128 1998 55 63
35. K.J. O'Byrne, M.I. Koukourakis, A. Giatromanolaki Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer Br J Cancer 82 2000 1427 1432
36. N.J. Robert, V. Diéras, J. Glaspy RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer J Clin Oncol 29 2011 1252 1260
37. A.M. Brufsky, S. Hurvitz, E. Perez RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer J Clin Oncol 29 2011 4286 4293
38. C. Puppin, F. Puglisi, M. Pandolfi Histone deacetylase inhibitors induce thymidine phosphorylase expression in cultured breast cancer cell lines Oncol Rep 26 2011 309 314
39. M. Toi, H. Bando, S. Horiguchi Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer Br J Cancer 90 2004 2338 2343
40. M. Kurosumi, T. Tabei, K. Suemasu Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients Oncol Rep 7 2000 945 948
41. F. Puglisi, C. Andreetta, F. Valent Anthracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells Anticancer Drugs 18 2007 883 888
42. R.M. Layman, D.G. Thomas, K.A. Griffith Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer Clin Cancer Res 13 2007 4092 4097
43. H. Li, Z. Suo, Y. Zhang The prognostic significance of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in breast carcinomas Histol Histopathol 19 2004 129 136
44. F. Puglisi, G.G. Cardellino, D. Crivellari Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer Ann Oncol 19 2008 1541 1546
45. C. Andreetta, C. Puppin, A. Minisini Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer Ann Oncol 20 2009 265 271
46. H.Y. Zhao, H. Huang, Z.H. Hu Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy Anticancer Drugs 23 2012 534 542